Myriad Genetics
MYGN
190 hedge funds and large institutions have $1.91B invested in Myriad Genetics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 28 closing their positions.
24,360% more call options, than puts
Call options by funds: $17.1M | Put options by funds: $70K
69% more capital invested
Capital invested by funds: $1.13B → $1.91B (+$778M)
1.75% more ownership
Funds ownership: 99.52% → 101.27% (+1.8%)
4% less funds holding
Funds holding: 197 → 190 (-7)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
19% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 75
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$32.3M |
| 2 |
GCM
Glenview Capital Management
New York
|
+$22.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$15.9M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$11.6M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.48M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.81M |
| 3 |
Morgan Stanley
New York
|
-$5.51M |
| 4 |
EARNEST Partners
Atlanta,
Georgia
|
-$4.95M |
| 5 |
BlackRock
New York
|
-$4.64M |
MYGN Hedge Fund Activity: Q1 2023 in Review
190 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2023, worth a combined $1.91B — up 69% from $1.13B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of MYGN and 23 opened new positions — a net loss of 5 holders — while 75 trimmed existing stakes and 61 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $32.3M. The largest seller was State Street, cutting an estimated $8.48M.
- 190 institutional investors held Myriad Genetics (MYGN) as of Q1 2023, down from 197 in Q4 2022.
- Funds reported $1.91B of Myriad Genetics stock for Q1 2023, up 69% quarter-over-quarter.
- 23 funds opened new Myriad Genetics positions in Q1 2023 and 28 closed out, a net change of -5 holders.
- The largest Myriad Genetics buyer in Q1 2023 was Balyasny Asset Management, an estimated $32.3M added.
- The largest Myriad Genetics seller in Q1 2023 was State Street, an estimated $8.48M sold.
Based on aggregated 13F filings for Q1 2023.